Polyoxometalates as potent inhibitors for acetyl and butyrylcholinesterases and as potential drugs for the treatment of Alzheimer's disease

Medicinal Chemistry Research

Volumn 22, Issue 3, 2013, Pages 1224-1228

  Iqbal, Jamshed ^a   Barsukova Stuckart, Maria ^b   Ibrahim, Masooma ^b   Ali, Syed Usman ^a   Khan, Aftab Ahmed ^a   Kortz, Ulrich ^b  

^a COMSATS Institute of Information Technology ^*  (Pakistan)

^b JACOBS UNIVERSITY BREMEN   (Germany)

Author keywords

Acetylcholinesterase; Anti Alzheimer; Butyrylcholinesterase; Enzyme Inhibition; Polyoxometalates

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; POLYOXOTUNGSTATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AQUEOUS SOLUTION; ARTICLE; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; MOLECULAR SIZE;

EID: 84874118811     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0125-8     Document Type: Article

References (39)

1. Acerete R, Server-Carrio J, Vegas A, Martinez-Ripoll M (1990) Synthesis and x-ray crystal structure determination of a novel chiral heteropolyanion: the "3:1" octadecatungstohexaphosphate. J Am Chem Soc 112:9386-9387
2. Alptuzun V, Prinz M, Horr V, Scheiber J, Radacki K, Fallarero A, Vuorela P, Engels B, Braunschweig H, Erciyas E, Holzgrabe U (2010) Interaction of (benzylidene-hydrazono)-1,4-dihydropyridines with beta-amyloid, acetylcholine, and butyrylcholine esterases. Bioorg Med Chem 18:2049-2059
3. Barnard DL, Hill CL, Gage T, Matheson JE, Huffman JH, Sidwell RW, Otto MI, Schinazi RF (1997) Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res 34:27-37
4. Contant R, Klemperer WG, Yaghi O (2007) Potassium Octadecatungstodiphosphates(V) and Related Lacunary Compounds. In: Inorganic Syntheses, pp 104-111: John Wiley & Sons, Inc
5. Damonte EB (1996) Antiviral agents that act in the early phases of the viral cycle. Rev Argent Microbiol 28:204-216
6. Dan K, Miyashita K, Seto Y, Fujita H, Yamase T (2002) The memory effect of heteropolyoxotungstate (PM-19) pretreatment on infection by herpes simplex virus at the penetration stage. Pharmacol Res 46:357-361
7. De Clercq E (1995) Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 8:200-239
8. De Clercq E (1997) Antiviral metal complexes. Met Based Drugs 4:173-192
9. Dong Z, Tan R, Cao J, Yang Y, Kong C, Du J, Zhu S, Zhang Y, Lu J, Huang B, Liu S (2011) Discovery of polyoxometalate-based HDAC inhibitors with profound anticancer activity in vitro and in vivo. Eur J Med Chem 46:2477-2484
10. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95
11. Flutsch A, Schroeder T, Grutter MG, Patzke GR (2011) HIV-1 protease inhibition potential of functionalized polyoxometalates. Bioorg Med Chem Lett 21:1162-1166
12. Fukuma M, Seto Y, Yamase T (1991) In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus. Antiviral Res 16:327-339
13. Geisberger G, Paulus S, Carraro M, Bonchio M, Patzke GR (2011a) Synthesis, characterisation and cytotoxicity of polyoxometalate/carboxymethyl chitosan nanocomposites. Chemistry 17:4619-4625
14. Geisberger G, Paulus S, Gyenge EB, Maake C, Patzke GR (2011b) Targeted delivery of polyoxometalate nanocomposites. Small 7:2808-2814
15. Geng J, Li M, Ren J, Wang E, Qu X (2011) Polyoxometalates as inhibitors of the aggregation of amyloid beta peptides associated with Alzheimer's disease. Angew Chem Int Ed Engl 50:4184-4188
16. Guo R, Cheng Y, Ding D, Li X, Zhang L, Jiang X, Liu B (2011) Synthesis and antitumoral activity of gelatin/polyoxometalate hybrid nanoparticles. Macromol Biosci 11:839-847
17. Hu D, Shao C, Guan W, Su Z, Sun J (2007) Studies on the interactions of Ti-containing polyoxometalates (POMs) with SARS-CoV 3CLpro by molecular modeling. J Inorg Biochem 101:89-94
18. Ingkaninan K, Temkitthawon P, Chuenchom K, Yuyaem T, Thongnoi W (2003) Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. J Ethnopharmacol 89:261-264
19. Inoue M, Suzuki T, Fujita Y, Oda M, Matsumoto N, Iijima J, Yamase T (2006a) Synergistic effect of polyoxometalates in combination with oxacillin against methicillin-resistant and vancomycin-resistant Staphylococcus aureus: a high initial inoculum of 1 x 108 cfu/ml for in vivo test. Biomed Pharmacother 60:220-226
20. Inoue M, Suzuki T, Fujita Y, Oda M, Matsumoto N, Yamase T (2006b) Enhancement of antibacterial activity of beta-lactam antibiotics by [P2W18O62]6-, [SiMo12O40]4-, and [PTi2W10O40]7- against methicillin-resistant and vancomycin-resistant Staphylococcus aureus. J Inorg Biochem 100:1225-1233
21. Judd DA, Nettles JH, Nevins N, Snyder JP, Liotta DC, Tang J, Ermolieff J, Schinazi RF, Hill CL (2001) Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. J Am Chem Soc 123:886-897
22. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Muller CE, Eltzschig HK (2007) CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116:1784-1794
23. Komloova M, Musilek K, Horova A, Holas O, Dohnal V, Gunn-Moore F, Kuca K (2011) Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors-implications for early myasthenia gravis treatment. Bioorg Med Chem Lett 21:2505-2509
24. Korabecny J, Musilek K, Holas O, Binder J, Zemek F, Marek J, Pohanka M, Opletalova V, Dohnal V, Kuca K (2010) Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett 20:6093-6095
25. Kortz U, Jameson GB, Pope MT (1994) Polyoxometalate diphosphate complexes. Folded macrocyclic dodecatungstates, [(O3PXPO3)4W12O36]16-(X = O, CH2). J Am Chem Soc 116:2659-2660
26. Marco JL, de los Rios C, Garcia AG, Villarroya M, Carreiras MC, Martins C, Eleuterio A, Morreale A, Orozco M, Luque FJ (2004) Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2 + channels and nicotinic receptors. Bioorg Med Chem 12:2199-2218
27. Müller CE, Iqbal J, Baqi Y, Zimmermann H, Rollich A, Stephan H (2006) Polyoxometalates-a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. Bioorg Med Chem Lett 16:5943-5947
28. Prudent R, Moucadel V, Laudet B, Barette C, Lafanechere L, Hasenknopf B, Li J, Bareyt S, Lacote E, Thorimbert S, Malacria M, Gouzerh P, Cochet C (2008) Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 15:683-692
29. Prudent R, Sautel CF, Cochet C (2010) Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2. Biochim Biophys Acta 1804:493-498
30. Rouleau J, Iorga BI, Guillou C (2011) New potent human acetylcholinesterase inhibitors in the tetracyclic triterpene series with inhibitory potency on amyloid beta aggregation. Eur J Med Chem 46:2193-2205
31. Samadi A, Chioua M, Bolea I, de los Ríos C, Iriepa I, Moraleda I, Bastida A, Esteban G, Unzeta M, Gálvez E, Marco-Contelles J (2011) Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem 46:4665-4668
32. Sarafianos SG, Kortz U, Pope MT, Modak MJ (1996) Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft. Biochem J 319(Pt 2):619-626
33. Sartorel A, Truccolo M, Berardi S, Gardan M, Carraro M, Toma FM, Scorrano G, Prato M, Bonchio M (2011) Oxygenic polyoxometalates: a new class of molecular propellers. Chem Commun (Camb) 47:1716-1718
34. Shigeta S, Mori S, Yamase T, Yamamoto N (2006) Anti-RNA virus activity of polyoxometalates. Biomed Pharmacother 60:211-219
35. Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia E, Muller CE, Murakami T, Robson SC (2010) CD39/ENTPD1 expression by CD4 + Foxp3 + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139:1030-1040
36. Tasso B, Catto M, Nicolotti O, Novelli F, Tonelli M, Giangreco I, Pisani L, Sparatore A, Boido V, Carotti A, Sparatore F (2011) Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. Eur J Med Chem 46:2170-2184
37. Wall MJ, Wigmore G, Lopatar J, Frenguelli BG, Dale N (2008) The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition. Neuropharmacology 55:1251-1258
38. Yanagie H, Ogata A, Mitsui S, Hisa T, Yamase T, Eriguchi M (2006) Anticancer activity of polyoxomolybdate. Biomed Pharmacother 60:349-352
39. Zhang G, Keita B, Craescu CT, Miron S, de Oliveira P, Nadjo L (2007) Polyoxometalate binding to human serum albumin: a thermodynamic and spectroscopic approach. J Phys Chem B 111:11253-11259